Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent ARID1A-mutant lung adenocarcinoma: a case report

Immune checkpoint inhibitors (ICIs) have reshaped the management of advanced non-small cell lung cancer (NSCLC), yet only a subset of patients derive durable benefit and reliable predictive biomarkers remain limited. AT-rich interaction domain 1A (ARID1A) alterations have been identified as potential modulators of tumor immunogenicity, although clinical evidence of durable benefit in NSCLC remains limited. We report a case of sustained and complete remission following chemo-immunotherapy in a patient with ARID1A-mutant lung adenocarcinoma treated at the time of locoregional recurrence.